Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial
KEYWORDS: warfarin, rivaroxaban, manufacturer, committee, erg, population, people, risk, model, trial, stroke, treatment, noted, analysis, etexilate

who tended to have a lower risk of stroke. The Committee heard that people with atrial fibrillation treated with warfarin in primary care often have a CHADS score of less than 2 and that it is estimated that between 20 and 75% 2 of people with atrial fibrillation and a CHADS score of less than 2 are prescribed 2 warfarin in the UK. Only 0.02% of the trial population had a CHADS score less 2 than 2. The clinical specialists agreed that it was likely that although people with a CHADS score of 2 or more would benefit similarly to those in the ROCKET-AF 2 trial, this cannot be assumed for people with a CHADS score of less than 2. The 2 Committee noted the comments received during consultation that suggested that consultees and commentators had differing opinions on the generalisability of the results of ROCKET-AF to UK clinical practice. The Committee was made aware by the manufacturer that a systematic review of the literature had suggested that there does not appear to be an interaction between treatment effect and baseline CHADS risk. The Committee heard from the manufacturer that rivaroxaban would 2 be indicated for atrial fibrillation in people
